

# Local Anesthesia in Dentistry

## A Locoregional Approach

*Jesús Calatayud, MD, PhD, DMD*

*Associate Professor (retired)*

*Pediatric Dentistry*

*School of Dentistry*

*Universidad Complutense. Madrid (Spain)*

*Mana Saraghi, DMD, DADBA*

*President, American Dental Board of Anesthesiology*

*Director, Dental Anesthesiology Residency Program, Jacobi Medical Center*

*Assistant Professor of Dentistry, Albert Einstein College of Medicine*

*Bronx, New York (United States)*

**WILEY Blackwell**

This edition first published 2024  
© 2024 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Jesús Calatayud and Mana Saraghi to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

*Registered Offices*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

*Limit of Liability/Disclaimer of Warranty*

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

*Library of Congress Cataloging-in-Publication Data*

Names: Calatayud, Jesús, author. | Saraghi, Mana, author.

Title: Local anesthesia in dentistry: a locoregional approach / Jesús Calatayud, Mana Saraghi.

Description: Hoboken, NJ: Wiley-Blackwell, 2023. | Includes bibliographical references and index.

Identifiers: LCCN 2023007820 (print) | LCCN 2023007821 (ebook) | ISBN 9781394180158 (cloth) | ISBN 9781394180165 (adobe pdf) | ISBN 9781394180172 (epub)

Subjects: MESH: Anesthesia, Dental-methods | Anesthesia, Local-methods | Anesthesia, Dental-adverse effects | Anesthesia, Local-adverse effects | Anesthetics, Local

Classification: LCC RK510 (print) | LCC RK510 (ebook) | NLM WO 460 | DDC 617.9/676-dc23/eng/20230420

LC record available at <https://lcn.loc.gov/2023007820>

LC ebook record available at <https://lcn.loc.gov/2023007821>

Cover Design: Wiley

Cover Image: © Christine von Diepenbroek/Getty Images

Set in 9.5/12.5pt STIXTwoText by Straive, Pondicherry, India

## Contents

**Preface** *xxiii*

**About the Companion Website** *xxv*

### **1 History of Local Anesthesia in Dentistry** *1*

The Coca Leaf *1*

Cocaine *2*

The Development of the Syringe *3*

The Dangers of Cocaine *4*

Adrenaline and the Vasoconstrictive Effect *4*

Novocaine or Procaine *5*

The Development of Local Anesthesia in Dentistry *5*

Local Anesthetics *5*

Vasoconstrictors *6*

Instruments *7*

Anesthetic Techniques *7*

Twenty-First Century Developments *8*

Frequency of Use of Local Anesthesia in Dentistry *9*

References *9*

### **Applied Anatomy** *15*

### **2 Applied Anatomy I: Maxillary Arch** *17*

Introduction *17*

The Trigeminal Nerve *17*

Trigeminal Ganglion *17*

Trigeminal Nerve: Functions *17*

Maxillary Nerve (V<sub>2</sub>) *17*

Overview of Collateral Branches *18*

Intracranial Zone *18*

Pterygopalatine Fossa Zone *18*

Infraorbital Zone *19*

Palatine Nerves *19*

Greater Palatine Nerve *20*

Nasopalatine Nerve *20*

Superior Alveolar Nerves *22*

Posterior Superior Alveolar Nerve (PSAN) *22*

Middle Superior Alveolar Nerve (MSAN) *22*

Anterior Superior Alveolar Nerve (ASAN) *23*

Superior Dental Plexus *23*

Other Structures of Interest *24*

Greater Palatine Canal and Foramen	24
Greater Palatine Canal	24
Greater Palatine Foramen	24
Nasopalatine Canal and Foramen	24
Nasopalatine Canal	24
Nasopalatine Foramen	24
Cortical Bone Thickness	25
Pterygoid Venous Plexus	25
Infraorbital Foramen	25
Pterygopalatine Fossa	26
Margins	26
Content	27
Glossary	27
References	28

### 3 Applied Anatomy II: Mandibular Arch 31

Mandibular Nerve (V <sub>3</sub> )	31
Overview	31
Buccal Nerve	31
Course	32
Innervation	32
Auriculotemporal Nerve	33
Course	33
Innervation	33
Lingual Nerve	33
Course	33
Innervation	34
Remarks	34
Inferior Alveolar Nerve	34
Course	34
Innervation	35
Remarks	35
Mylohyoid Nerve	36
Course	36
Innervation	36
Body of the Mandible	36
Cortical Bone Thickness	36
Retromolar Zone (Trigone and Fossa)	37
Retromolar Trigone	37
Retromolar Fossa	37
Mandibular Canal	37
Mental Foramen	38
Ramus of the Mandible	39
Divergent Angle	39
Ramus Width	39
Lingula	39
Mandibular Foramen	39
Sulcus colli	40
Coronoid Notch	41
Accessory Foramina	41
Pterygomandibular Space	41
Anatomic Boundaries of the Pterygomandibular Space	42
Open/Closed Mouth and Pterygomandibular Space	44

Contents of the Pterygomandibular Space	44
Sphenomandibular Ligament	44
Positive Aspirations and Hematomas	45
Glossary	46
References	46

#### 4 The Peripheral Nerve and Local Anesthesia 50

Peripheral Nerve Microanatomy	50
Neurons	50
Sensory Neurons	50
Axons	50
Membranes	51
Nerve Fibers and Myelin	51
Myelinated Fibers	51
Unmyelinated Fibers	52
Nerve Fiber Classification	52
Peripheral Nerve Structure	52
Basic Membrane Proteins	54
Sodium–Potassium Pump	54
Sodium Channels	54
Potassium Channels	55
Peripheral Nerve Neurophysiology	56
Fundamentals	56
Membrane Potentials: Membrane at Rest (Polarized)	56
Action Potentials: Excited Membrane	56
Phase 1: Depolarization	57
Phase 2: Repolarization	57
Phase 3: Hyperpolarization	57
Propagation of the Action Potential	58
Mechanisms of Local Anesthesia	58
Mechanism	58
Differential Nerve Block	58
Tonic and Phase Block	59
Critical Length	59
Transient Receptor Potential Channel	60
Nerve Block Kinetics	60
Induction Stage	60
Recovery Stage	60
Re-Injection	61
Tachyphylaxis	61
Resistance to Local Anesthetics	61
References	62

#### Pharmacology 65

#### 5 Local Anesthetics 67

Chemical Structure	67
Physical-chemical Characteristics of Local Anesthetics	67
Dissociation Constant or pKa	68
Partition Coefficient or Lipid Solubility	69
Protein Binding	70
Vasodilation	70

Assessment of Anesthesia and the Anesthetic Parameter	70
Assessment of Local Anesthesia in Dentistry	70
Anesthetic Parameter	72
Anesthetic Concentration	72
Concentration and Volume	72
Concentration and Safety	73
Concentration and Anesthetic Potency	73
Concentration and Tissue Irritation	73
Maximum Doses	74
Maximum Doses for Children	75
Pregnancy and Lactation	76
Pregnancy	76
Lactation	77
Mixing Local Anesthetics	77
Isomers	78
References	79

## 6 Vasoconstrictors 85

Introduction	85
Advantages	85
Disadvantages	85
Dilutions and Concentrations	87
Catecholamines	87
Isomers and Catecholamines	88
Adrenergic Receptors	88
Systemic Effects	90
Heart	90
Circulatory System	91
Respiratory Tract	91
Endocrine System and Metabolism	91
Uterus	91
Vasoconstrictive Effect	91
Catecholamine Metabolism	92
Epinephrine	92
Norepinephrine	93
Levonordefrin	94
Phentolamine (OraVerse®)	95
OraVerse®	96
Advantages and Indications	96
Technique and Dose	96
Clinical Efficacy	97
Tolerance, Toxicity, and Adverse Side Effects	97
Felypressin (Octapressin®)	98
Cardiovascular Effects	98
Vasoconstrictive Effect	99
Adverse Effects	100
Contraindications	100
Advantages and Disadvantages	100
Maximum Doses	100
Combinations of Vasoconstrictors	101
References	101

## 7 Injectable Anesthetic Solutions Used in Dentistry 107

Solution Composition 107

Local Anesthetic 107

Vasoconstrictor 107

Antioxidants (Sulfites) 107

Preservatives (Methylparaben) 108

pH Adjustment 108

Other Compounds 109

Procaine (Novocaine) 109

Metabolism 109

Procaine with Epinephrine 109

Remarks 109

Lidocaine (Lignocaine) 109

Metabolism 111

Remarks 111

Indications 111

Standard 2% Lidocaine: L-100 with 1:100 000 (10 µg/ml) Epinephrine or L-80 with 1:80 000 (12.5 µg/ml) Epinephrine 111

L-50, 2% Lidocaine with 1:50 000 (20 µg/ml) Epinephrine 113

Articaine 113

Metabolism 115

Remarks 115

Maximum Dose and Toxicity 115

Anesthetic Potency 115

Anesthetic Effect 116

Indications 116

A-100, 4% Articaine with 1:100 000 (10 µg/ml) Epinephrine 116

A-200, 4% Articaine with 1:200 000 (5 µg/ml) Epinephrine 117

Mepivacaine 117

Metabolism 117

Remarks 119

Maximum Doses 119

Mepivacaine Solutions 119

Indications 119

Prilocaine (Propitocaine) 120

Metabolism 120

Remarks 120

Toxicity and Safety 120

Clinical Efficacy 122

Prilocaine Solutions 122

Indications and Contraindications 122

Indications 122

Contraindications 123

Bupivacaine 123

Metabolism 123

Remarks 123

Indications and Contraindications 125

Indications 126

Contraindications 126

References 126

## Contraindications 133

### 8 Contraindications for Local Anesthetic Techniques in Dentistry 135

- Lack of Cooperation from the Patient 135
  - Predisposing Factors 135
  - Evaluation of Risk 136
  - Approach to Behavioral Problems 136
- ASA IV Physical Status 137
  - ASA I Patients 137
  - ASA II Patients 137
  - ASA III Patients 138
  - ASA IV Patients 139
  - ASA V Patients 140
- Clotting Abnormalities 140
  - High-risk Anesthetic Techniques 140
  - Systemic Causes of the Risk of Hemorrhage 140
    - Antiplatelet Agents 140
    - Oral Vitamin K Antagonists: Anticoagulants 141
    - Direct Oral Anticoagulants 141
    - Low Platelet Counts 142
    - Hemophilia 142
  - Alternatives and Recommendations 142
- Other Contraindications 142
  - Injection Site Infection 142
  - Impossible Physical Access 143
- Summary 143
- References 143

### 9 Contraindications for Local Anesthetics 148

- Relevant Contraindications 148
  - Allergy to Local Anesthetics 148
  - Long-acting Anesthetics 148
  - Prilocaine, Benzocaine, and Methemoglobinemia 148
  - Cholinesterase Deficiency and Esther Anesthetics 149
  - Myasthenia Gravis and Esters 149
- Minor Contraindications 149
  - Procaine and Sulfonamides 149
  - Lidocaine and Cimetidine 150
  - Lidocaine and Propranolol 150
  - Lidocaine and Succinylcholine 150
  - Bupivacaine and Cardiotoxicity 150
  - Amide Anesthetics and Malignant Hyperthermia 151
- References 151

### 10 Contraindications for Vasoconstrictors 155

- Absolute Contraindications 155
  - Uncontrolled Insulin-dependent Diabetes Mellitus 155
  - Intolerance to Sulfites 156
  - Asthma Controlled with Corticosteroids 156
  - Pheochromocytoma-induced Arterial Hypertension 156
  - Recent Consumption of Cocaine 157
  - Patients with Cardiovascular Diseases Who Take Amphetamines and Psychostimulants 157

Allergy to Vasoconstrictors	157
Relative Contraindications	158
Nonselective Beta-blockers	158
COMT Inhibitor-type Antiparkinson Drugs	160
ASA III Patients with Cardiovascular Conditions	160
Digitalis Glycosides (Digoxin)	160
Amphetamines and Psychostimulants	161
Tricyclic Antidepressants	161
Interactions Involving Drugs that are No Longer in Use	162
Older Antihypertensive Agents (Anti-adrenergic Drugs)	162
General Anesthesia (Halothane and Thiopental)	162
Contraindications of Little Relevance	163
Uncontrolled Hyperthyroidism	163
Phenothiazines and Antipsychotic Drugs	163
Vasoconstrictors and Osteoradionecrosis	164
Contraindications of Felypressin	164
References	165

## **Instruments and Topical Anesthesia 171**

### **11 Instrument Set and Equipment 173**

Needles	173
Parts of a Needle	173
Anterior Part	173
Middle Part	174
Posterior Part	174
Protective Sheath	175
Lengths and Gauges	175
Needles: Critical Aspects	175
Aspiration and Gauge	176
Pain and Gauge	176
Deflection of the Needle and Gauge	176
Lesions Caused by a Barbed Needle	177
Breakage of Needles	177
Criteria for the Selection of Needles	177
Cartridges	177
Parts of a Cartridge	178
Anterior Part or Needle Adapter	178
Neck	178
Cylindrical Body	178
Posterior Part	179
Other Elements	179
Storage of Cartridges	179
Norms for All Cartridges	179
Norms for Cartridges Containing Catecholamines	179
Problems Affecting Cartridges	180
Degradation of Drugs in the Cartridge	180
Local Anesthesia	181
Sympathomimetic Vasoconstrictors (Epinephrine)	181
Sulfites	181
Syringes	181

Parts of a Cartridge-type Syringe	181
Anterior Part or Needle Adapter	181
Syringe Barrel or Body of the Syringe	182
Posterior Part (Back)	182
Piston	182
Using the Syringe	182
Set-up	182
Dismantling	182
Cleaning and Sterilization	183
Self-aspirating Syringes	183
Characteristics	183
Mechanism of Action	184
Advantages and Disadvantages	184
Variants of Cartridge-type Syringes	184
Plastic Syringes	184
Uniject-type Syringes	184
Disposable Antineedle Stick Syringes	184
Power-operated Syringes	185
Other Injection Devices	185
Additional Instruments	185
Complementary Devices	185
Alkalinization System (pH Onset System®)	186
Advantages	186
Mechanism of Action	186
Cartridges for the Device	187
Mixing Pen	187
Mixing	188
pH	188
Vibrating Devices	188
Gate Control Theory	189
VibraJect	189
DentalVibe	189
Cartridge Heaters	190
References	190

## 12 Topical Anesthesia 195

Factors Affecting Topical Anesthesia with Local Anesthetics	195
Local Anesthetic	195
Application Time	195
Method of Application	195
Amount Administered	196
Types of Pain	196
Area of the Mouth	197
Effect of Topical Anesthesia	197
Topical Anesthetics in Dentistry	197
Benzocaine	197
Maximum Dose	197
Advantages and Disadvantages	197
Specific Adverse Effects	198
Lidocaine	199
Maximum Dose	199
Advantages and Disadvantages	199

Specific Adverse Effects	199
Lidocaine Adhesive Patches (DentiPatch®)	199
Maximum Dose	199
Advantages and Disadvantages	199
Specific Adverse Effects	200
EMLA Cream	200
Advantages of the Structure and Composition of EMLA	200
Maximum Dose	200
Advantages and Disadvantages	200
Specific Adverse Effects	201
Tetracaine (Amethocaine)	201
Maximum Dose	201
Advantages and Disadvantages	201
Specific Adverse Effects	201
Cocaine	203
Maximum Dose	203
Advantages and Disadvantages	203
Specific Adverse Effects	203
Formulations for Use in Dentistry	203
Topical Anesthetic Compounds	203
Composition	203
Advantages and Application	205
Adverse Effects	205
Clinical Efficacy	205
Other Experimental Formulations	205
Topical Cooling	206
Cold Aerosols	206
Refrigerants	207
Topical Ice	207
Indications for Topical Anesthetic	208
For Symptomatic Relief of Pain	209
Pain Resulting from Tooth Decay	209
Painful Ulcers and Lesions on the Mucosa	209
Indication as Anesthetic	209
Minor Surgical Interventions	209
Clinical Procedures	209
Management of the Gag Reflex	209
Periodontal Oraqix® Gel	209
Oraqix System (Needle-free Anesthesia)	210
Method of Application	210
Efficacy	211
Specific Adverse Effects	211
References	211

## Local Anesthetic Techniques in Dentistry 217

### 13 Basic Injection Technique 219

Comment on Retraction	219
Phases of the Injection	219
Initial Preparation	219
Preparation Phase	220

Application of Topical Anesthetic	222
Method of Application	222
Observations on Aerosols	223
Transfer of the Syringe	223
Insertion of the Needle	225
Aspiration	226
False Positives and Negatives	226
How to Interpret a Positive Aspiration	227
Aspiration Technique	227
Remarks	228
Injection	228
Final Phase	229
Evaluation of Anesthesia	230
Post-treatment Phase	231
Causes of Pain During the Injection	232
Factors That Cause Pain	232
Factors That Play a Role in Pain	232
Unimportant Causes (Myths)	233
Terminology	234
Appendix	235
References	235

## 14 Maxillary Anesthesia I: Pulpal Anesthesia 241

Introduction	241
Maxilla	241
Maxillary Nerve (V <sub>2</sub> )	241
Buccal Anesthesia of the Upper Molars	241
Buccal Infiltration	242
Zones Anesthetized	242
Technique	242
Efficacy of this Technique	245
Complications Specific to this Technique	245
Factors That Lead to Success	245
Modified Cotton Roll Approach	245
Infraorbital Nerve Block	245
Uses	246
Zones Anesthetized	246
Intraoral Technique	246
Extraoral Technique	248
Efficacy of this Technique	249
Complications Specific to this Technique	249
Remarks	250
Posterior Superior Alveolar Nerve Block	251
Zones Anesthetized	251
Technique	251
Efficacy of this Technique	252
Complications Specific to this Technique	253
Modified Adata Technique	253
High Tuberosity Approach	253
Uses	253
Zone Anesthetized	254
Technique	254

Efficacy of this Technique	256
Complications Specific to this Technique	256
Remarks	256
Transpalatal Technique	256
Uses	257
Zone Anesthetized	257
Technique	257
Efficacy of this Technique	260
Complications Specific to This Technique	261
Factors That Lead to Success	263
Final Remarks	263
References	263

## 15 Maxillary Anesthesia II: Complementary Anesthesia of the Palate 267

Introduction	267
The Nasopalatine Nerve Innervates Less than Previously Thought	267
The Potency of the Anesthetic is not Important	267
Anesthesia of the Palate Without Complementary Palatal Anesthesia	267
Indications	268
Methods for Reducing Pain in Palatal Techniques	269
Topical Anesthesia	269
Pressure Techniques	270
Topical Cooling	270
Periodontal Ligament Technique	270
Minimal Intervention Technique	271
Nasopalatine Nerve Block	271
Anesthetized Area	271
Technique	271
Specific Complications of This Technique	273
Intranasal Variant	274
Technique	274
Greater Palatine Nerve Block	274
Area Anesthetized	274
Technique	275
Specific Complications of This Technique	276
Partial Variant of the Palate	276
Transpapillary Technique in Children	276
Technique	277
References	278

## 16 Mandibular Anesthesia I: Pulpal Anesthesia 281

Mandibular Block: General Remarks	281
Zone Anesthetized	282
Factors to Consider for the Mandibular Block	282
Efficacy is Correlated to the Location of Tooth in the Mandible	282
High Failure Rate	283
Unreliability of Lower Lip Anesthesia	283
Sequential Nature	283
The Longer the Time, the More Intense the Anesthesia	283
Minor Effect of the Type of Anesthetic	283
Impact of the Volume Injected	284
Minor Effect of the Specific Mandibular Block Technique	284

Bilateral Mandibular Blocks	284
Long, Caliber 25G Needles	284
Slow Injection	285
Mandibular Block: Conventional or Direct Technique	285
Distribution of the Anesthetic Solution	285
Zone Anesthetized	286
Technique	286
Efficacy of this Technique	291
Complications Specific to this Technique	291
Mandibular Block: Gow-Gates Technique	292
Mechanism	292
Advantages, Disadvantages, and Non-advantages	294
Advantages	294
Disadvantages	294
Non-advantages	295
Zone Anesthetized	296
Technique	296
Efficacy of this Technique	299
Complications Specific to this Technique	299
Remark on the Gow-Gates Technique	300
Mandibular Block: Laguardia–Akinosi Technique	300
Advantages and Disadvantages	300
Use	301
Distribution of the Anesthetic Solution	301
Zone Anesthetized	301
Technique	301
Efficacy of this Technique	303
Complications Specific to this Technique	303
Double Infiltration in Anterior Teeth	304
Keys to Success	304
Zone Anesthetized	304
Technique	304
Efficacy of this Technique	306
Complications Specific to this Technique	306
References	307

## **17 Mandibular Anesthesia II: Complementary Anesthesia** 312

Introduction	312
Indications	312
Lingual Nerve Block	312
Anesthetized Area	312
Technique	312
Complications of this Technique	314
Partial Variant as Complementary Anesthesia	314
Buccal Nerve Block	314
Anesthetized Area	315
Technique	315
Specific Complications of this Technique	316
References	316

## **18 Supplementary Techniques in Cases of Failure** 318

Introduction	318
Intrapulpal Anesthesia	318

Traditional Technique	318
Keys to a Successful Approach	318
Intrapulpal Technique	319
Topical Anesthetic Technique	319
Technique	319
Periodontal Ligament Technique (PDL)	320
Indications and Contraindications	320
Indications	320
Contraindications	320
Diffusion of the Solution	320
Factors that Determine Efficacy	321
Major Factors	321
Minor Factors	321
Instrument Set	322
Syringes	322
Needles	324
Cartridges	324
Anesthetized Area	324
Technique	324
Efficacy of This Technique	326
Specific Complications of the Technique	326
Complications Due to Performance of the Technique	326
Periodontal Abnormalities	326
Pulpal Abnormalities	327
Cardiovascular Abnormalities	328
Intraseptal Technique	328
Factors Underlying a Successful Technique	328
Contraindications	328
Anesthetized Area	328
Technique	328
Specific Complications of the Technique	329
Intraosseous Technique	329
Indications, Contraindications, and Disadvantages	330
Instrument Set	330
Stabident®	330
X-Tip®	331
Anesthetic Solutions	331
Anesthetized Area	331
Intraosseous Technique	332
Efficacy	336
Specific Complications	336
Complications Due to Mechanical Aspects	336
Postoperative Complications	337
Pulpal Abnormalities	338
Final Remarks	338
References	339

## **19 Failure of Dental Local Anesthesia** 344

Frequency	344
Consequences of Failure	344
Failures: General Causes	345
Highly Anxious Patients	345
Patients with Drug Addiction and Alcoholism	346

Teeth Affected by Irreversible Acute Pulpitis	346
Reasons for Failure of Anesthesia in Acute Pulpitis	346
Approach	347
Resistance to Local Anesthetics	348
Other Causes of Failure	348
Specific Failures After Maxillary Infiltration	348
Causes of Maxillary Failure	348
Approach	349
Specific Failures After Mandibular Block	349
Reasons for Failure After Mandibular Block	349
Failure Owing to Inappropriate Technique	349
Failure for Anatomical Reasons	349
Failure Arising from Accessory Innervation	350
Approach	354
References	354

## 20 Alternatives to Conventional Techniques 360

Jet Injection	360
Distribution of the Solution	360
Indications	361
Disadvantages	361
Advantages	361
Equipment	361
Syrijet®	361
Injex®	362
Technique	362
Complications of this Technique	363
Electronic Anesthesia: Electronic Dental Anesthesia	364
Mechanism of Action	364
Indications	364
Disadvantages	366
Advantages	366
Contraindications	366
Equipment	367
Technique	367
Complications of this Technique	368
Computer-Controlled Injection Systems (The Wand®)	368
Description of the Device	369
Central Processing Unit	369
Foot Control	370
Handpiece	370
Needles	370
Set-up	370
Advantages and Disadvantages	371
P-AMSA	371
Anesthetized Area	371
Technique	371
Efficacy of the P-AMSA Technique	373
Specific Complications of this Technique	373
Advantages of the P-AMSA Technique	373
P-ASA	373
Anesthetized Area	373

Technique	374
Efficacy of P-ASA	375
Specific Complications with this Technique	375
Advantages of P-ASA	375
The Wand and Conventional Techniques	375
Periodontal Ligament Technique	375
Mandibular Block	376
Other Computer-controlled Injection Systems	376
Comfort Control Syringe from Midwest	376
Quicksleeper	377
Equipment	377
Anesthetized Area	377
Transcortical Technique	377
Efficacy of QuickSleeper	378
Disadvantages	379
Intranasal Maxillary Local Anesthesia (Kovanaze®)	379
Composition of the Solution	379
Zone Anesthetized	379
Indications and Contraindications	379
Indications	379
Contraindications	380
Equipment	380
Preparation	380
Technique	380
Efficacy of the Technique	381
Complications Specific to this Technique	381
Advantages and Disadvantages	383
Advantages	383
Disadvantages	384
References	384

## 21 Local Anesthesia in Children 389

The Problem with Children and Adolescents	389
Local Anesthetic Solutions	389
Anesthetic Technique in Children	390
Anesthesia of the Primary Mandibular Molars	391
Needles and Mandibular Block	392
Remarks on Buccal Infiltration	392
References	392

## Complications 395

## 22 Local Complications of Dental Local Anesthesia 397

Persistent Post-injection Pain	397
Self-inflicted Injury	397
Facial Blanching	398
Anesthetic Techniques Involved	399
Clinical Manifestations	399
Causes and Pathophysiology	399
Proposed Causes	399
Pathophysiology	400

Localized Late-onset Skin Lesion	400
Clinical Manifestations	400
Causes and Pathophysiology	400
Ischemic Necrosis Due to Vasospasm	400
Type III Allergic Reaction	401
Facial Hematomas	401
Technical Factors Contributing to Hematomas	401
Clinical Manifestations	401
Management by the Dentist	402
Nerve Lesions	402
Anatomical Lesions	402
General Causes	402
Immediate Electric Shock Sensation	403
Electric Shock Sensation After the Transpalatal Approach	403
Long-Term Paresthesia	404
Causes of Long-term Lesions	404
Clinical Manifestations	404
Management by the Dentist	406
Alterations of the Sense of Taste	407
Hoarseness	407
Trismus	407
Local Anesthetic Techniques Implicated in the Development of Trismus	407
Causes of Trismus	408
Clinical Types of Trismus	408
Acute Early-onset Trismus	408
Chronic Late-onset Trismus Due to Fibrous Band Formation	408
Chronic Late-onset Trismus Due to Infection	408
Treatment of Trismus	408
Conservative Treatment (Mechanical Therapy)	408
Forced Opening Under General Anesthesia	409
Surgical Drainage	409
Facial Palsy	409
Clinical Manifestations	410
Facial Palsy Associated with Mandibular Block	410
Immediate Onset and Short Duration	410
Late Onset and Long Duration	411
Facial Palsy Associated with Maxillary Infiltration	412
Ocular Complications	412
Anesthetic Techniques Involved	412
Clinical Manifestations	412
Other Clinical Aspects of Interest	413
Onset and Duration	413
Predictors of Sequelae	414
Management by the Dentist	414
Pathophysiology of Complications	414
Retrograde Arterial Flow	414
Retrograde Venous Flow	414
Passive Diffusion to the Orbit	417
Irritation of the Sympathetic System	417
Sympathetic System Block (Horner-like Syndrome)	418
Other Proposed Causes	418
Needle-induced Infection	418

Clinical Manifestations	418
Management by the Dentist	419
Post-injection Mucosal Ulceration	419
Clinical Manifestations	419
Proposed Causes	419
Management by the Dentist	419
Breakage of the Needle	419
Anesthetic Techniques Involved	420
Causes of Needle Breakage	420
Associated Factors of Interest	420
Clinical Manifestations	421
Decision to Retrieve (or Not)	421
Management by the Dentist	421
Preventive Measures	422
Breakage of the Cartridge in the Mouth	423
Aural Complications	423
Techniques Responsible	423
Clinical Manifestations	423
Management by the Dentist	424
References	424

## **23 General Complications of Dental Local Anesthesia 433**

Preventive Measures	435
Basic Management of Complications	435
Initial Measures	435
Unconscious Patient	436
P: Posture	436
A: Airway	436
B: Breathing	437
C: Circulation	438
Routes of Administration of Drugs	438
Calling the Emergency Services	439
Psychogenic Reactions	439
General Causes	439
Vasovagal Syncope	439
Pathophysiology	439
Predisposing Factors	440
Clinical Manifestations	440
Management by the Dentist	441
Prevention	442
Hyperventilation Syndrome	442
Pathophysiology	442
Clinical Manifestations	443
Differential Diagnosis	443
Management by the Dentist	443
Allergic-like Reactions	444
Toxicity Induced by Sympathomimetic Vasoconstrictors	444
Pathophysiology	444
Symptoms of Reaction to Epinephrine	444
Symptoms of Reaction to Norepinephrine	445
Management by the Dentist	445
Systemic Toxicity Induced by Local Anesthetics	445

Pathophysiology	445
Causes of Local Anesthetic-induced Toxicity	446
Inadvertent Intravascular Injection	446
Overdose	447
Rapid Absorption	447
Clinical Manifestations	447
First Phase: Initial	447
Second Phase: Advanced	448
Third Phase: Convulsions	448
Fourth Phase: Final	448
Clinical Variations	449
Management by the Dentist	449
Recovery and Discharge	450
Prevention	450
Toxic Methemoglobinemia	450
Local Anesthetics Involved	451
Benzocaine	451
Prilocaine	451
Other Anesthetics	451
Aggravating Factors	452
Clinical Manifestations	452
Management by the Dentist	453
Allergy	453
Allergy to the Components of Local Anesthetic Solution	455
Local Anesthetic	455
Esters	455
Amides	455
Vasoconstrictor	456
Antioxidants (Sulfites)	456
Preservative (Methylparaben)	457
Confusion with Other Reactions	457
Clinical Manifestations	458
Minor Manifestations	458
Major Manifestations	458
Diagnosis	459
Management by the Dentist	459
Treatment of Minor Manifestations	459
Treatment of Major Manifestations	459
Support Measures for Major Manifestations	460
Recovery and Discharge	460
Prevention	460
References	461

**Index** 469

**For Annexes: Refer Online**

## Preface

Dental local anesthesia is the principal means at our disposal for controlling the pain caused by our treatments and procedures. The importance of dental local anesthesia is so profound that it is impossible to imagine carrying out our work without it. This approach has considerable advantages and an excellent safety profile over other techniques for managing pain in our day-to-day activity as compared to sedation and general anesthesia. Furthermore, administration of local anesthesia is one of the most common procedures in clinical practice and is generally the first treatment administered. If its effect is inadequate, our work is complicated enormously.

Correct application of local anesthesia is very important in adults, since many patients may refuse to undergo dental treatment owing to their fear of needles and injections. Paradoxically, the method we use to control pain causes most anxiety for patients. Correct application is even more important in children, since traumatic experiences in childhood can be carried forward to adulthood: poor control of dental pain in children is one of the main factors underlying the development of anxiety over dental treatment at older ages.

We highlight a series of peculiar aspects in this book. Almost all of the techniques discussed are intraoral, and while extraoral techniques that cross the skin are used occasionally – mainly in hospitals – they have a negligible role in modern dentistry. In addition, many chapters and sections provide simple and practical quantitative data (percentages, means, ranges, etc.). This information has been obtained from many sources and studies with the aim of guiding dentists in the situations that arise in daily practice. The annexes found at the end of the book provide abundant information based on specific and practical data.

They are presented separately so as not to interrupt the flow and reduce the effectiveness of this textbook.

The images and illustrations aim to explain concepts as clearly as possible. Consequently, most drawings are more schematic than strictly topographic, much in the same style as that of the famous illustrator Frank H. Netter, who expressed the idea perfectly: “Clarification of a subject is the aim and goal of illustration. No matter how beautifully painted, how delicately and subtly rendered a subject may be, it is of little value as a medical illustration if it does not serve to make clear some medical point.” Of course, we do not aim to surpass the artistic quality of Dr. Netter, although we do hope to follow his approach. We have endeavored to provide clear criteria and practice guidelines. While these may occasionally be debatable, we believe that one criterion is better than none. In any case, every effort has been made to present practical and actionable information.

We would like to express our gratitude to Hilding Björn, lecturer at the Universities of Malmö and Lund, for providing us with studies on dental local anesthesia. We are also grateful to his son, Lars Olof Björn, for providing us with information on his father. We thank Professors Rafael Rioboo and Antonio Bascones of Universidad Complutense for their inspiration and example over so many years. We appreciate the help provided by all of the libraries involved in the search for documentation, namely, the Kungliga Biblioteket in Stockholm, the Library of the Academy of Sciences in Saint Petersburg, the British Library, the Centro de Información y Documentación Científica (Spain), and, in particular, the Library of the School of Dentistry of Universidad Complutense and its directors Rosa M<sup>a</sup> Rodríguez Durántez and Marian de la Casa, as well as all

their staff. Special mention must be made of all those students from the School of Dentistry, Universidad Complutense de Madrid who, over the years, provided information, documents, and studies on dental local anesthesia

Finally, we would like to stress that the information we provide is the fruit of enormous efforts made by many. Therefore, we wish to thank all those great professionals who have played a key role in the history of dentistry, as well as the thousands of specialists (chemists, physicians, and dentists) who, while not part of this history, made essential contributions to the development of techniques

that provide relief for millions of people every day throughout the world. We thank them all.

*Jesús Calatayud*

Associate Professor, School of Dentistry  
Universidad Complutense, Madrid, Spain

*Mana Saraghi*

Director, Dental Anesthesiology Residency Program,  
Jacobi Medical Center  
Assistant Professor of Dentistry,  
Albert Einstein College of Medicine  
Bronx, New York

## About the Companion Website

This book is accompanied by a companion website:

**[www.wiley.com/go/Calatayud/local](http://www.wiley.com/go/Calatayud/local)**



The website includes:

- The Annexes 1 to 42

## 1

## History of Local Anesthesia in Dentistry

The development of anesthesia in general and local anesthetics in particular required a cultural change. The concept of pain (especially obstetrical pain) was linked to the concept of original sin, and the ability to endure pain was regarded as a sign of character and, in men, was even associated with virility (Greene 1971).

The changes taking place in Western Europe between 1750 and 1850, with the enlightenment, industrialization, progressive democratization, and humanization of society, created an atmosphere favorable to the discovery of anesthetics. Nothing comparable occurred in Asia, Russia, or the Islamic countries, where feudalism persisted in a variety of forms. This general process altered the cultural, political, and religious climate, affecting a significant number of individuals (Greene 1971).

Dentists, not medical doctors, were responsible for the discovery of anesthesia, given their close day-to-day contact with pain and hence their motivation to seek the means to alleviate it (Greene 1971). Doctors focused more on infections than on pain, for people were dying of pneumonia, diphtheria, gangrene, tuberculosis, tetanus, puerperal fever, and appendicitis (Greene 1971; Vandam 1973). Two dentists were the first to introduce anesthesia: Horace Wells (1815–1848), with nitrous oxide in 1844 (Wells 1847; Menczer and Jacobsohn 1992; Jacobsohn 1994), and William Thomas Green Morton (1819–1868), with ether in 1846 (Greene 1979).

Local anesthesia, the basis of modern local anesthetics for dentistry, developed later. This chapter reviews the discovery and evolution of local anesthesia from the Spanish discovery of the coca leaf in America to recently established forms of local anesthesia in dentistry.

### The Coca Leaf

Coca leaves are taken from a shrub of the genus *Erythroxylum*, a member of the Erythroxylaceae family, so named by Patricio Browne because of the reddish hue of

the wood of the main species (Loza-Balsa 1992). Of the various species in this genus, *Erythroxylum coca* contains the highest concentration of the alkaloid known as cocaine in its leaves, up to 0.7–1.8% by weight (Caldwell and Sever 1974; Van Dyke and Byck 1982). Many species of this genus have been grown in Nicaragua, Venezuela, Bolivia, and Peru since pre-Columbian times (Loza-Balsa 1992).

The earliest cultivation and use of the coca leaf in the Bolivian and Andean region date back to 700 BCE (Loza-Balsa 1992), although recent discoveries in Ecuador indicate human usage more than 5000 years ago (Van Dyke and Byck 1982). Alfred Bühler premised that the Arhuaco, a tribe from the Negro River region, were the first to discover the properties of the drug and spread this knowledge to neighboring peoples (Bülher 1944a,b).

Sixteenth century Spanish chroniclers associated the appearance of coca with Francisco Pizarro's (1475–1541) conquest of the Inca or Tahuantinsuyo empire in 1532. The earliest chroniclers made no mention of the plant. The reason for the belated mention of the coca leaf and its consumption may lie, as the sixteenth century Spanish chroniclers aver, in the fact that its use was restricted to the ruling class of the Inca Empire and to certain religious rites, but did not extend to the population as a whole (Calatayud and González 2003). Modern authors have verified those assumptions; noting that after the fall of the empire in 1532 coca consumption became popular among the population at large (Gutierrez-Noriega and Zapata 1947; Loza-Balsa 1992) as the entire social system underwent drastic change, particularly after 1540 (Loza-Balsa 1992).

The first reliable account of coca leaf consumption is a manuscript letter from the Bishop of Cuzco, Friar Vicente de Valverde (15..–1542), to Emperor Charles V in 1539 (*Carta* 1864). His letter is important because Valverde accompanied Francisco Pizarro throughout the conquest of Peru and was present at all the significant events. The second reliable reference is another manuscript, also a letter, from the President of the Peruvian Assembly, member

of the clergy and man of letters Pedro de la Gasca (1485–1567), to the Council of the Indies in 1549, in which he described the measures taken by Francisco Pizarro to distribute coca (Carta 1954). The third reference, and the first to be published in print, is attributed to traveler Pedro Cieza de León (1520–1554) whose chronicle of Peru, published in Seville in 1553, refers to the chewing of coca leaves with a chalk-like powder to assuage hunger, and increase strength and stamina (Cieza de Leon 1553). Pedro Cieza traveled through America between 1530 and 1550, and lived in Peru from 1548 to 1550 (Cieza de Leon 1984). All these chroniclers observed that coca consumption was widespread throughout the population (Table 1.1).

The first reference to the anesthetic effects of coca is attributed to Spanish Jesuit Bernabé Cobo (1582–1657) (Torres 1943), who, in his 1653 manuscript work on the new world, mentioned that toothaches could be alleviated by chewing coca leaves (Cobo 1890).

In subsequent centuries, most writers tended to be apologists, stressing the stimulant effects of coca but paying little or no heed to its dangers. Physicians such as Peruvian José Hipólito Unanue (1755–1833) (Vicuña-Mackenna 1914) recommended the use of coca leaves in 1794 (Unanue 1914) while Austrian physician Sigmund Freud (1856–1939) recommended cocaine itself in 1884. Scholar Francisco Falcon draw attention to the dangers of coca for the first time, in 1582, on the grounds of the mortality it produced among the aboriginal peoples (although this was mainly due to disease acquired during its cultivation) and the difficulty of ridding oneself of the “custom” of using it. The choice of that word in sixteenth century usage is indicative of certain characteristics of addiction. Falcon also recommended measures to restrict its consumption (*Representación* 1946), but it was not until the nineteenth century that the voice of alarm was sounded about the negative effects of coca abuse. German doctor Eduard Friedrich Poeppig (1798–1868), who drew a detailed picture of coca leaf addiction after a voyage to the Amazon in 1827–1832, stressed the digestive changes, migraine, weakness, weight loss, and alterations of

personality it induced and the low public opinion of coca consumption and its consumers, who were more poorly regarded than alcoholics in Europe, and unable to give up their habit (Poeppig 1836). The most important landmarks in connection with the coca leaf are outlined in Table 1.1.


## Cocaine

The active principle of the coca leaf was first isolated in 1860 at Friedrich’s laboratory in Göttingen by German chemist Albert Niemann (1834–1861) (Niemann 1860; Bühler 1944b), who called it “cocaine.” Although Niemann unfortunately died the following year, his work was carried on by his disciple Wilhelm Lossen (1838–1906) (Bühler 1944b), who determined the correct molecular formula,  $C_{17}H_{21}NO_4$ , in 1865 (Lossen 1865). The structural formula of the new alkaloid was far from obvious and in fact was not fully known until chemist Richard Willstätter (1872–1942) analyzed it successfully in 1898 (Figure 1.1). He and his colleagues in Munich, and the Merck Laboratory in Darmstadt, synthesized artificial cocaine in 1923 (Willstätter 1898; Willstätter et al. 1923).

From the time cocaine was isolated, steps were taken to apply it as the first local anesthetic. Nothing had changed since the early reference to the anesthetic effect of the coca leaf by Jesuit Bernabé Cobo in 1653 (Cobo 1890). In 1860, Niemann reported and clearly demonstrated numbness of the tongue caused by the new alkaloid, an observation corroborated by Lossen in his 1865 paper (Lossen 1865). The first experimental study on cocaine, however, was conducted by Peruvian Thomas Moreno y Maíz, ex-naval surgeon, as part of his doctoral thesis published in Paris in 1868. While observing that injecting a cocaine solution in animals induced insensitivity to pain, he made no mention of its use in surgery (Moreno y Maíz 1868). In 1880, Russian aristocrat and physician Vassily von Anrep of the University of Würzburg published a paper on his experiments on animals, animal tissues and organs, and, especially, himself and recommended the use of cocaine as a surgical anesthetic (Anrep 1880).

**Table 1.1** Earliest descriptions of the coca leaf, its anesthetic effect, and harmful side effects.

Earliest writings on the coca leaf
• 1539 Friar Vicente de Valverde. Manuscript letter
• 1549 Pedro de la Gasca. Manuscript letter
• 1553 Pedro Cieza de León. First book in print
First description of the anesthetic effect
• 1653 Bernabé Cobo. Manuscript
First references to harmful effects
• 1582 Francisco Falcon
• 1836 Eduard Friedrich Poeppig



**Figure 1.1** Structural formula for cocaine.

The ground was laid but the final step had yet to be taken when Viennese ophthalmologist Carl Koller (1857–1944) rose to the challenge (Liljestrand 1967). Koller was working in the Wiener Allgemeines Krankenhaus (Viennese General Hospital) where he got to know and become friends with Sigmund Freud. Freud, interested in the stimulant effects of cocaine to overcome morphine addiction, encouraged Koller to participate in a series of experiments with cocaine during the spring and summer of 1884 (Buess 1944; Liljestrand 1967). Koller noted the numbing effect on his tongue when he swallowed the cocaine (Koller 1928). In July 1884, Freud published a review on cocaine and his experiments, again noting but without lending any particular attention to the alkaloid's anesthetic effect on mucous membranes (Freud 1884). It was Koller who grasped its importance, experimenting with animal corneas (Leonard 1998) as well as on himself and on patients (Koller 1884a). On 11 September 1884, he performed the first operation using local anesthetic on a patient suffering from glaucoma (Fink 1985). The German Ophthalmology Society Congress met in Heidelberg on 15–16 September 1884, but Koller was unable to attend. However, he asked Dr. Josef Brettau, an ophthalmologist from Trieste passing through Vienna on his way to Heidelberg, to read his paper at the Congress (Fink 1985). The impact was instantaneous. Koller himself read his paper on 17 October in the Wiener Medizinische Gesellschaft (Vienna's medical society) (Koller 1884a, 1928; Liljestrand 1967) and it was published on 25 October (Leonard 1998). Dr. Henry D. Noyes of New York, who attended the Heidelberg Congress, sent a summary highlighting Koller's work to the *New York Medical Record*, who published it on 11 October (Noyes 1884). Dr. Bloom translated Koller's article into English and had it published in *The Lancet* on 6 December (Koller 1884b). The news of Koller's findings appeared in other publications of the time and sparked the development of regional and local anesthesia. Between September 1884 and late 1885, 60 publications concerning local anesthesia using cocaine appeared in the United States and Canada (Matas 1934a).

Vassily von Anrep (1852–1927) published the first report of a truncal block in an intercostal nerve on 15 November (Yentis and Vlassakov 1999) and Dr. William Stewart Halsted (1852–1922) and his co-worker Richard John Hall (1856–1897) read Noyes's report and immediately became interested in local anesthesia (Olch and William 1975). On 6 December 1884, Hall published a report on the first mandibular block. Dr. Nash of New York was able to block the infraorbital plexus with 8 minims (about 0.5 ml) of 4% cocaine hydrochloride to obturate an upper incisor, while Dr. Halsted performed a mandibular block of the inferior alveolar nerve in a medical student using 9 minims of the

**Table 1.2** Stages in the discovery of the local anesthetic effect of cocaine in late 1884.

Month and day in 1884	Landmark
July	<ul style="list-style-type: none"> <li>• Sigmund Freud publishes his paper on cocaine (Freud 1884)</li> </ul>
11 September	<ul style="list-style-type: none"> <li>• First operation using cocaine as a local anesthetic, performed by Carl Koller on a glaucoma patient (Fink 1985)</li> </ul>
15–16 September	<ul style="list-style-type: none"> <li>• German Ophthalmological Society congress at Heidelberg (Liljestrand 1967)</li> </ul>
11 October	<ul style="list-style-type: none"> <li>• Henry D. Noyes publishes a summary of the Heidelberg proceedings in the <i>New York Medical Record</i> (Noyes 1884)</li> </ul>
17 October	<ul style="list-style-type: none"> <li>• Carl Koller reads his paper at the Vienna Medical Society (Koller 1928; Liljestrand 1967)</li> </ul>
25 October	<ul style="list-style-type: none"> <li>• Carl Koller publishes his paper in the <i>Wiener Medizinische Wochenschrift</i> (Koller 1884a)</li> </ul>
15 November	<ul style="list-style-type: none"> <li>• von Anrep reports implementing the first intercostal block (Yentis and Vlassakov 1999)</li> </ul>
6 December	<ul style="list-style-type: none"> <li>• J.N. Bloom translates Koller's paper and publishes it in <i>The Lancet</i> (Koller 1884b)</li> <li>• Richard John Hall describes the first application of local anesthesia in dentistry and the first mandibular block, effected by William Stewart Halsted (Hall 1884)</li> </ul>

same solution (Hall 1884). In 1892, François Franck coined the term “block” to describe this type of local anesthesia (Matas 1934b). The most significant milestones in the discovery of local anesthesia based on cocaine in late 1884 are listed in Table 1.2.

## The Development of the Syringe

The development of local anesthesia was contingent on the invention of the hypodermic syringe for subcutaneous injections. Subcutaneous administration of medication had already begun by way of incisions in the skin. Von Neuner developed an early syringe in 1827 to introduce fluids into animals (McAuley 1966), and in 1841 the American firm Zophar Jayne, working out of Illinois, began to market its syringe, but to be used it required a prior incision in the skin (McAuley 1966). According to Charles Pfender's studies of the origin of hypodermic medication (Pfender 1911) the first to use injection by syringe was Irish surgeon Francis

Rynd (1801–1861) of Meath Hospital. In 1845, he reported two cases of morphine acetate injection (Rynd 1845). One of the cases was an injection in the vicinity of the supraorbital nerve to treat neuralgia. Rynd failed to publish the design of his syringe until 1861 (Rynd 1861). In 1853, veterinary surgeon Charles Gabriel Pravaz (1791–1855) of Lyon developed a syringe to inject iron perchloride into animals to treat aneurysm (Pravaz 1853). At almost at the same time, in 1855, the Scottish physician Alexander Wood (1817–1884) (Pfender 1911) published a report of nine cases treated with muriate of morphia, which he had injected via a syringe (Wood 1855). From then on, the hypodermic syringe was readily available to the medical community. Wood was instrumental in the extension of its use, although it was Charles Hunter who first used the term “hypodermic” to refer to these subcutaneous methods of injection in 1859 (Pfender 1911; Matas 1934a).

## The Dangers of Cocaine

After Koller’s discovery of its local anesthetic powers, the use of cocaine spread rapidly, but since it was administered in high concentrations, on the order of 10–30% (Pernice 1890; Mayer 1924; McAuley 1966), practitioners soon began to report its alarming side-effects. Between 1884 and 1891, 200 cases of systemic intoxication and 13 deaths attributable to the drug were recorded (Anonymus 1979), quenching enthusiasm for it and prompting physicians to turn to gases such as nitrous oxide and ether, particularly for minor surgical procedures, including dentistry (Sauvez 1905). Around this time, the dependence liability of cocaine also began to emerge as several early users, Freud and Halsted among them, fell victims to it (Liljestrand 1967; Olch and William 1975).

The credit for making the infiltration of cocaine safer is shared by a number of researchers. In Germany, Maximilian Oberst of Halle (1849–1925) (Buess 1944) applied low concentrations of cocaine to the fingers, compressing them for slower release of the drug into the bloodstream, a technique that proved to be effective, as reported on 3 April 1890 by another scientist from Halle, Ludwig Pernice, who had worked with Oberst (Pernice 1890). On 11 June 1892, Carl Ludwig Schleich (1859–1922), a surgeon from Berlin, published the results of a study using a solution of 0.1–0.2% cocaine hydrochloride, infiltrating it under several layers of skin and chilling the area with an ether aerosol (to fix the drug and enhance its effects) (Schleich 1892). Parisian surgeon Paul Reclus (1847–1914), in turn, published a paper in 1895 in which he described the use of low concentrations of cocaine (from 2% to 0.5%) to achieve a good local anesthetic which, though slower in taking hold, caused no side effects

(Reclus 1895). The operations described in Reclus’s work included dental extractions and pulpotomies.

Today we know that around the same time Halsted was working with solutions containing low cocaine concentrations, to be applied by compression, but he unfortunately became addicted to cocaine and morphine, and was unable to publish his results (Matas 1934b; Olch and William 1975; Fink 1985). The maximum cocaine dosage for infiltration was eventually established at 50 mg (Fischer 1912; Bieter 1936).

## Adrenaline and the Vasoconstrictive Effect

From the outset, as discussed above, the development of local anesthesia went hand in hand with studies to improve its effectiveness and safety. The clinical experiments reported by Leonard Corning on 19 September 1885 are a case in point. Corning showed that using compression and a tourniquet on the limbs prevented cocaine from diffusing from the injection site, thereby increasing and deepening its anesthetic effect, in turn making it possible to reduce the dose administered (Corning 1885).

Toward the end of the nineteenth century, the Polish researcher Napoleon Cybulski (1854–1919) (Grybowski and Pietrzak 2013) unsuccessfully attempted to isolate the active principle of the suprarenal medulla, which increased arterial pressure (Cybulski 1895). A similar attempt was made by Dr. John Jacob Abel (1857–1938), a researcher from the Johns Hopkins hospital, who while coming very close, always isolated contaminated forms (Abel and Crawford 1897; Abel 1898, 1899). Abel named his substance “epinephrine” (from the Greek *epi* and *nephros* “on top of the kidneys”) (Abel 1899). In that same time frame, Austrian physician Otto Ritter von Fürth (1867–1938) also unsuccessfully attempted to isolate the substance, which he called “suprarenin” (von Fürth 1900). In 1901 two researchers, Jokichi Takamine (1854–1922) (Takamine 1901a,b) and Thomas Bell Aldrich (1861–1939) (Aldrich 1901), did isolate the compound, which Takamine called “adrenalin” (from the Latin *ad* and *renal* “near the kidney”) and for which Aldrich determined the correct molecular formula, namely  $C_9H_{13}NO_3$ . In 1904, German Friedrich Stolz (1860–1936) synthesized adrenaline or epinephrine in its two isomeric forms levo (L) and dextro (D) (Stolz 1904). At present, only the more powerful levo form is used.

The clinical application of adrenaline as a local anesthetic is attributed to Leipzig surgeon Heinrich Braun (1862–1934) (Braun 1903a). Braun obtained epinephrine from the London Parke Davies laboratories and added it to a cocaine solution in 1903, achieving a deeper and longer-lasting anesthetic effect, which he called a chemical

tourniquet (Braun 1903a,b). Braun subsequently conducted a series of experiments with animals and patients to evaluate different cocaine and epinephrine concentrations (Braun 1903b).

Today, for reasons traceable to its history, this vasoconstrictor is known as epinephrine in the United States and adrenaline in Europe and the rest of the world. Takamine patented the technique and marketed the product with Parke Davis as “adrenalin” (without the final “e”) (Navarro 2003). Inasmuch as Adrenalin was a registered trade name in the United States, the American Medical Association’s Council on Pharmacy and Chemistry chose epinephrine as the generic name for the active principle (Smith 1920). Chemists and physicians in the rest of the world, however, not subject to such pharmaceutical company interests, chose the name “adrenaline” (with the final “e”), which is now the term used by the European Pharmacopoeia, the World Health Organization (WHO) and the International Union of Pure Applied Chemistry (IUPAC) (Navarro 2003).

## Novocaine or Procaine

As soon as the undesirable effects of cocaine began to appear (such as cardiovascular toxicity and dependence liability), attempts were made to find new drugs with anesthetic properties to replace it. However, none of these attempts were very successful until 27 November 1904, when German chemist Alfred Einhorn (1856–1917) (Link 1959) patented 18 derivatives of para-aminobenzoic acid, developed in the Meister Lucius und Brüning factories at Höchst. Composition number two was to bring radical change (Farbwerke vorm 1904).

Professor Heinrich Braun published the first paper on what he called novocaine (Figure 1.2) in 1905, comparing it to other promising local anesthetics such as stovaine and alypin (Braun 1905). Braun compared different concentrations of novocaine with adrenaline and obtained excellent results (Braun 1905). In 1909, Einhorn and his disciple Emil Uhlfelder published a paper outlining the properties and chemical characteristics of novocaine (Einhorn and Uhlfelder 1909).

Novocaine was introduced in North America by W.S. Schley in 1907 and more specifically into dentistry by

Hermann Prinz in 1910 (Rahart 1972). In 1910, German dentist Guido Fischer (1877–1959) published the first book on local anesthesia in dentistry, in which he described the novocaine-based local anesthetic techniques already in use in dentistry as opposed to the anesthetic gases applied until then (Fischer 1910). The book was enormously successful, with a second edition translated into English by Richard Riethmüller in 1912 (Fischer 1912) and the fifth edition translated into Spanish in 1924 (Fischer 1924). A number of editions of Fischer’s work were published in the early twentieth century and translated into various languages. The second major text to appear on local anesthesia in dentistry, authored by Kurt Hermann Thoma of Harvard in 1914, was likewise based on novocaine (Thoma 1914). Novocaine replaced cocaine, ushering in the modern era of local anesthesia and allowing for the development of new, more effective, and safer techniques (Matas 1934b).


As the patent for novocaine was German, during the First World War the United States Government provided its chemical industry with the formula to manufacture the drug without having to depend on the German license and, in an attempt to protect their product, changed the name to procaine. When the war ended, Germany lost the patent (Smith 1920; Benedict et al. 1932; Nevin and Puterbaugh 1949; Link and Alfred Einhorn 1959). Today novocaine is more commonly known as procaine (Figure 1.2).

## The Development of Local Anesthesia in Dentistry

Much progress has been made since local anesthesia first came into general use. The following discussion, not intended to be exhaustive, highlights the major twentieth and twenty-first century developments in anesthesia, vasoconstriction, instruments, and techniques used in dentistry.

### Local Anesthetics

As discussed above, the first local anesthetic was cocaine, but the risks it entailed soon prompted the pursuit of other drugs. In 1890 Eduard Ritser (1859–1946) developed benzocaine, sold under the trade name “Anästhesin.” As it is scanty water-soluble however, it was used as a topical anesthetic (Nueve Arneimittel 1902). Novocaine, as noted earlier, was synthesized in 1904. It was safe, but since its effects were weak, it called for the addition of large quantities of adrenaline, especially for infiltration. To overcome the problem, in 1919 Alfred Kneucker of Vienna began to use 4% instead of 2% novocaine (Kneucker 1919). These concentrations were marketed in the United States beginning



**Figure 1.2** Structural formula for novocaine, labeled procaine.

in 1941 (Dobbs 1965). In 1944, however, the American Dental Association's Council on Dental Therapeutics disallowed them (Council on Dental Therapeutics 1944) on the grounds that toxicity increased geometrically with linear increases in concentration. In other words, 1 ml of 2% novocaine is four times as toxic as 1 ml of a 1% solution (Waters 1933). Their decision was also influenced, no doubt, by the reminiscence of the tragic consequences in the late nineteenth century of high concentrations (10–30%) of cocaine and the safety afforded by diluted doses (Pernice 1890; Schleich 1892; Reclus 1895). In 1949, Frank Everett not only showed that 4% novocaine solutions were indeed more effective than 2% solutions (both mixed with epinephrine) but that the 50% lethal dose (LD50), administered intravenously in rabbits and subcutaneously in rats, varied very little with concentration and, in fact, only depended on the total dose administered (Everett 1949). The Council on Dental Therapeutics has accepted the use of 4% novocaine ever since (Dobbs 1965).

In 1928, Otto Eisleb (1887–1948) synthesized a new local anesthetic, tetracaine, distributed under the trade name Pantocaine (Eisleb 1934). Tetracaine is very powerful but unfortunately also very toxic and its effects are delayed. The 2% novocaine and 0.15% tetracaine solution introduced by Cook-Waite in 1940 was intended to prolong and intensify the effects of the anesthetic (Dobbs 1965).

Novocaine, however, posed new problems, in the form of allergic reactions in patients and dentists (Guptill 1920; Klauder 1922). Since cartridge syringes were not in use at the time and dentists did not use gloves, the skin on their fingers was frequently in contact with the anesthetic. In 1920, Arthur Guptill reported the first case of allergic dermatitis in one such professional (Guptill 1920).

These developments led to a search for an alternative to novocaine, but of the many developed in the first half of the twentieth century, none proved to be clearly better. In 1943, Swedish chemists Nils Isak Löfgren (1913–1967) and Bengt Lundqvist (1922–1953) synthesized a xylylidine derivative called lidocaine, chemically very different from novocaine, but safe, more powerful, and virtually allergy-free (Löfgren and Lundqvist 1946; Gordh et al. 2010). On the grounds of the studies conducted by Hilding Björn (1907–1995) and Sven Huldt, it came to be considered the standard local anesthetic and remains the standard to this day (Björn and Huldt 1947). Around that time Björn authored another breakthrough, a method to assess the efficacy of local anesthetic solutions in dental practice by electrically stimulating teeth with a pulp tester, which delivers objective data on pulpal anesthesia and its duration, overcoming the bias inherent in earlier, more subjective methods (Björn 1946, 1947). In 1948, Astra Pharmaceutical Products Inc. introduced lidocaine in the

United States and Sweden (Gordh et al. 2010). New amide-type anesthetics began to make their appearance soon after. In 1957, for instance, mepivacaine and bupivacaine were developed by Bo af Ekenstam et al. (1957) and the former was marketed in the United States by Cook-Waite in 1960 (Dobbs 1965). Nils Löfgren and Cläes Tegner synthesized prilocaine in 1960 (Löfgren and Tegner 1960) and in 1972 Adams et al. developed etidocaine (Adams et al. 1972). Articaine was synthesized in 1969 (Frenkel 1989; Rahn and Ball 2001; Malamed 2004) by Roman Muschaweck (Rahn and Ball 2001; Vogel 2007) at Hoechst AG, Frankfurt, and Winther and Nathalang (1972) published the first paper on the substance in 1972.

One characteristic development in the history of local anesthetics is the steady downward trend in the recommended doses used in dentistry. Thus, for instance, the maximum dose of novocaine recommended by Fischer in 1910 was 500 mg (Fischer 1910), whereas today it is 400 mg (American Dental Association 1984). The 1000 mg maximum dose of lidocaine initially recommended (Lozier 1949; Gordh et al. 2010) has now been lowered to 300 mg (American Dental Association 1984). With mepivacaine the original recommendation for 7.9 mg/kg was later reduced to 6.6 mg/kg (Zinman 1976) and today stands at 4.3 mg/kg (American Dental Association 1984).

### Vasoconstrictors

The first and to date the best vasoconstrictor, epinephrine, continues to be widely used, although maximum concentrations and doses have changed. In 1910, Fisher recommended maximum doses of 312 µg (Fischer 1912) and Mayer no more than 1000 µg (Mayer 1924). The concentrations used in those days were on the order of from 1:20 000 (50 µg/ml) to 1:40 000 (25 µg/ml) (Fischer 1912; Thoma 1914; Hein 1917; Smith 1920; Steadman 1923). The aim of these high concentrations was to strengthen the weak effects of novocaine.

In 1938, Tainter showed that 2% novocaine solutions together with 1:25 000 (40 µg/ml) epinephrine caused nervous reactions such as shaking and sweating in 42% of patients and dizziness in 9%, due to high concentrations of epinephrine. Reducing the concentration to 1:50 000 (20 µg/ml) led to a significant decline in such reactions (Tainter et al. 1938). In 1953, the Council of the New York Institute of Clinical Oral Pathology sought an official report from the New York Heart Association (NYHA) on the administration of epinephrine to cardiovascular patients. In October 1954, the NYHA recommended a maximum concentration of 1:50 000 (20 µg/ml) and an absolute maximum dose of 200 µg (Report of the Special Committee of the New York Heart Association 1955). In 1964, the

American Dental Association, in conjunction with the American Heart Association, confirmed the NYHA recommendations for the maximum epinephrine concentration and dose (ADA-AHA 1964).

Until 1931, epinephrine was the only vasoconstrictor allowed by the Council on Dental Therapeutics (1931), although nordefrin hydrochloride (cobefrin, corbadrine, or corbasil) was introduced in 1933 at concentrations of 1:10000 (100 µg/ml) by Cook-Waite laboratories (Dobbs 1965). In 1940, Mizzy Laboratories Inc. introduced phenylephrine (neosynephrine) at concentrations of 1:2500 (400 µg/ml) (Dobbs 1965). Levonordefrin, the levo isomer of nordefrin, was proven to be more powerful than the dextro form in 1957 (Moose 1959). In 1946, Swedish researcher Ulf Svante von Euler (1905–1983) (Gordh et al. 2010) was the first to isolate norepinephrine (Von Euler 1946a, 1946b), the more potent levo form of which was introduced in the 1950s (Dobbs and de Vier 1950; Epstein et al. 1951; Berling and Björn 1951). In the end, however, of all the sympathomimetic vasoconstrictors developed, the original, epinephrine, has proved to be the safest and most powerful. Noradrenaline is not only less effective in anesthetizing pulp with different local anesthetics (Berling and Björn 1951; Brown 1968), but more dangerous insofar as it may provoke blood pressure spiking (Boakes et al. 1972; Okada et al. 1989).

Felypressin (octapressin), a vasopressin (a hormone produced by the posterior lobe of the pituitary gland) derivative synthesized by Vigneaud et al. in 1953, constitutes a wholly different approach to vasoconstrictors (Du Vigneaud et al. 1953). As a polypeptide unrelated to sympathetic-mimetic substances governed by an entirely different mechanism, it can be used where the latter are contraindicated. Felypressin is used at concentrations of 0.03 International Units, i.e. a concentration of 1:1 850 000 (0.54 µg/ml), with 3% prilocaine. It was studied in 1966 by Cläes Berling with satisfactory results, although not as good as 2% lidocaine with 1:80 000 (12.5 µg/ml) epinephrine (Berling 1966). Felypressin is presently marketed in a number of European countries, but not in the United States.

## Instruments

Early in the use of local anesthesia, and especially in the first few decades of the twentieth century, needles were re-usable, thick (Fischer 1912; Smith 1920), and made of platinum, steel, or a platinum–iridium alloy (Fischer 1912; Thoma 1914; Tompkins 1921). They broke easily (Blum 1919; Tompkins 1921) and the steel models corroded with use (Fischer 1912; Thoma 1914; Tompkins 1921). Needles made of new stainless-steel alloys were introduced in the 1940s and were not only stronger but finer in caliber,

down to 25-gauge (25G) (Harrison 1948; Bump and Roche 1973). In 1959, the Cook-Waite and Roehr laboratories introduced disposable, sterilized needles to prevent viral hepatitis (Dobbs 1965). Modern disposable needles with new alloys are highly resistant to breakage and come in even finer calibers, 27G or 30G, although they tend to bend rather easily (Robison et al. 1984).

Becton and Dickinson glass syringes appeared in 1897 and glass ampoules of novocaine and epinephrine solution were introduced in 1914 (Dobbs 1965). Prior to their appearance, dentists had to mix the solution themselves by dissolving anesthetic tablets in distilled water with salts (Fischer 1912). Around 1920, military surgeon and World War I veteran Harvey S. Cook devised the cartridge system (a cartridge containing the anesthetic attached to a syringe) which, much like a rifle cartridge, could be loaded and injected into a single patient (Dobbs 1965), enhancing safety, sterilization, and speed (Nevin and Puterbaugh 1949). Later, Cook-Waite introduced a cartridge he called a “car-pule,” a name that became so popular that even today cartridges are known as carpules in many dental clinics (Nevin and Puterbaugh 1949). In 1935, the Novocol Chemical Company brought out vacuum-packed cartridges, extending the shelf life of solutions, and in 1947 the same company introduced a kind of screw at the upper end of the syringe plunger and a thumb ring for aspiration (Nevin and Puterbaugh 1949; Dobbs 1965).

The first papers on aspiration prior to injection appeared at the end of the 1950s (Harris 1957; Seldin 1958) and in 1957 the Council on Dental Therapeutics recommended routine aspiration before any injection (Council on Dental Therapeutics 1957). Self-aspirating, cartridge-type syringes appeared in the early 1970s (Evers 1971; Cowan 1972; Corkery and Barret 1973), although the first self-aspirating cartridge, attributed to Niels Bjorn Jorgensen (1894–1974), was designed in the early 1960s (Monheim 1965).

## Anesthetic Techniques

US surgeon William Stewart Halsted (1852–1922) was the first to block the mandibular nerve in 1884 (Hall 1884), although he left no record of whether the technique used was intra- or an extra-oral. In his 1910 book, German dentist Guido Fischer (1877–1959) (Groß 2018) described and popularized the indirect mandibular nerve block, otherwise known as the 1–2–3 technique (Fischer 1912) attributed to Braun in 1904 (Lindsay 1929). In 1924, Boris Levitt of New York developed the direct technique (Levitt 1924), also known as the conventional technique because it is the one most commonly used even today. In 1940, Laguardia of Montevideo developed a closed-mouth mandibular block technique (Laguardia 1940), which was rediscovered by

Akinosi of Lagos in 1977 (Akinosi 1977). In 1973, a new mandibular block technique was described by Australian dentist George Albert Edward Gow-Gates (1910–2001), which he had been perfecting since 1947 but which had not been published earlier (Gow-Gates 1973; Gow-Gates and Watson 1989).

Intraligamentary injection, one of the oldest techniques known, was first described by Emilie Sauvez of Paris in 1905 (Sauvez 1905), but as he did not lay claim to it as an original technique, it may have been in use prior to that date, perhaps in 1904 by Guido Fischer. Although Cassamani of Paris wrote his doctor's thesis on this technique in 1924 (Cassamani 1924), it was not included in the scientific literature until the 1970s, when it was described by Robert Lafargue (1973) and Chenaux et al. (1976). In 1981, a paper by Richard Walton et al. retrieved the method for the English-speaking world (Walton and Abbott 1981). According to Mendel Nevin and Pliny Guy Puterbaugh, the intra-pulp technique was first used in 1895 (Nevin and Puterbaugh 1949).

The foremost technique for blocking the upper maxillary nerve behind the tuberosity (high tuberosity approach) was developed after 1913 by Arthur Ervin Smith and described in 1920 (Smith 1920). The greater palatine foramen technique was first described by Juan Ubaldo Carrea (1883–1956) of Buenos Aires in 1921 (Carrea 1921).

Another technique for administering anesthetic solutions is high-pressure jet injection, based on high-pressure injection of a flow of very fine droplets which penetrate the skin and mucus and get into the tissues. It was used on human beings for the first time in 1947 by Frank Figge et al. (Figge and Scherer 1947). That same year, another paper describing a device called hypospray (Hingson and Hughes 1947) was published, but this device was not used in dentistry until Margetis et al. implemented it in 1958 (Margetis et al. 1958). The dermojet, an instrument specifically designed for dentistry, was developed in 1960 (Roberts and Sowray 1987). New and improved devices continued to be developed, the most prominent of which is the syrijet introduced in 1971 (Bennett and Monheim 1971; Epstein 1971).


Power-operated injection systems constitute another group of techniques for administering anesthetics. The history of the use of electricity has been revised (Kane and Taub 1975; Malamed and Joseph 1987), with the consensus being that the first reference was authored by Scribonius Largus, a Roman physician during the period of Tiberius and Claudius (first century) (Chinchilla 1841). In his treatise *de Compositionibus Medicamentorum* (Scribonii 1529) Largus described the use of an electric fish [the marbled electric ray (*Torpedo marmorata*): Kane and Taub 1975] to alleviate pain. Centuries later, in Wesley 1760, Methodism

founder John Wesley (1703–1791) published *The Desideratum*, in which he addressed the application of electrodes to relieve pain. The first reference in the application of electrodes to alleviate tooth-related pain was penned by another British scientist, James Ferguson, in 1770 (Ferguson 1770). In 1858, Jerome B. Francis reported 164 cases of electricity-mediated painless tooth extractions after the application of electrodes to the teeth in an article published in *The Dental Reporter* (Francis 1858). The impact of Francis's paper in the United States and Europe was enormous in the years thereafter, but its influence declined due to the poor results obtained in the late nineteenth and early twentieth centuries. As early as 1858, the London College of Dentists advised against its use because electricity was found to have no anesthetic effects and heighten pain and the few favorable results were attributable to “distraction” (Kane and Taub 1975). With the description of gate control theory (Melzack and Wall 1965) in 1965 and the mechanisms of pain modulation, truly operative systems have begun to be developed. In medicine, a technique known as TENS (transcutaneous electrical nerve stimulation) is used, whose equivalent in dentistry is called EDA (electronic dental anesthesia) (Malamed et al. 1989). The first practical system to be marketed for use in dentistry was Ultracalm in 1989 (Silverstone 1989) and more recently in 1994, 3M brought out a smaller and more accessible piece of equipment specifically applicable to dentistry, which goes by the name of Dental Electronic Anesthesia System, 8670 3M Dental (Croll and Simonsen 1994).


Power-driven injection systems are yet another technique for administering anesthetic solutions. Spring-driven or gas-actuated syringes introduced in the 1970s were designed to inject solutions while maintaining a constant pressure and hence a more uniform injection flow (Roberts and Sowray 1987). In 1997 a new, even more sophisticated apparatus called “the Wand” appeared, a computerized injection system developed by Dr. Mark Hochman of New York that automatically adapts the pressure to ensure a slow and constant flow at all times (Friedman and Hochman 1997) and separating injection rate from pressure. All these systems have built-in aspiration.

## Twenty-First Century Developments

*Oraqix® gel* was introduced to the market in 2005. As a derivative of eutectic mixture of local anesthetic (EMLA) cream it contains 5% topical anesthetic in a 1:1 eutectic blend of 2.5% lidocaine and 2.5% prilocaine, but designed for use in the oral cavity. It is a noninjectable, thermoreversible anesthetic gel characterized by low viscosity at ambient temperature. When introduced into the



**Figure 2.1** Trigeminal nerve (V cranial nerve) and its ganglion arising from the pons (view from base of brain).



**Figure 2.3** Trigeminal ganglion, lodged intracranially in the middle cranial fossa in the petrous part of the temporal bone, and branches.

fissure and courses along the roofless infraorbital groove on the floor of the orbit. It subsequently traverses the roofed infraorbital canal (continuous with the groove), changing its name from maxillary (V<sub>2</sub>) to infraorbital nerve, to the infraorbital foramen where it distributes its terminal branches.

### Overview of Collateral Branches

The maxillary nerve (V<sub>2</sub>) distributes collateral branches in four areas along its course (Figure 2.4).


#### Intracranial Zone

As it exits the ganglion, the maxillary nerve gives off the meningeal branch that innervates areas of the dura mater.


#### Pterygopalatine Fossa Zone

Located within the infratemporal fossa (formerly the zygomatic fossa), the pterygopalatine fossa is an inverted pyramid. It is bound posteriorly by the pterygoid apophysis in the sphenoid bone and anteriorly by the maxillary tuberosity. The anterior–posterior distance at the base (upper side) is 12–15 mm (Cook 1950a; Canter et al. 1964; von Arx et al. 2020). The following branches proceed from this fossa:

- 1) The zygomatic nerve, which penetrates the orbit through the inferior orbital fissure, branching into:
  - The zygomaticotemporal nerve, which innervates the skin on the forehead and eyelid.



**Figure 2.2** Areas of the face innervated by each of the three branches of the trigeminal nerve: (1) ophthalmic nerve (V<sub>1</sub>); (2) maxillary nerve (V<sub>2</sub>); (3) mandibular nerve (V<sub>3</sub>).




**Figure 2.5** Course of greater palatine nerve from pterygopalatine fossa, across pterygopalatine ganglion to palate.

### Greater Palatine Nerve

After traversing the pterygopalatine ganglion without exchanging fibers, the greater palatine nerve enters the pterygopalatine fossa, descending along the greater palatine canal (Figure 2.5), which opens into the pterygopalatine fossa vertex (Cook 1950b; von Arx et al. 2020). Initially formed as a vertical groove on the maxillary surface of the palatine, it is converted into a canal by articulation with the maxillary tuberosity and pterygoid process of the sphenoid. Here the nerve distributes a branch to innervate the inferior nasal concha. The canal also transmits the descending palatine artery (branch of the maxillary).

The greater palatine nerve arises in the hard palate after crossing the greater palatine foramen (Figure 2.6), accompanied by its artery, here named the greater palatine artery. It passes forward in the hard palate between the periosteum and the fibromucosa to the canine and lateral incisor zone, where it runs across the nasopalatine nerve. It innervates:


- The anterior-most part of the soft palate fibromucosa.
- The fibromucosa, periosteum, and hard palate from the molars up to the second premolar (100%), as far forward as the midline of the palate and the first premolar (95%), canine (75%), or lateral incisor (50%) (Langford 1989; Calatayud 2001) (Figure 2.7).
- Rarely, the pulp of the upper molars at the palate root (Ulusoy and Alacam 2014).




**Figure 2.6** Origin of greater palatine nerve and distribution in hard palate. *Source:* Redrawn from Roberts and Sowray (1987).

### Nasopalatine Nerve

Also known as Scarpa's nerve, or *nervus incisivus*, the nasopalatine nerve, after traversing the pterygopalatine ganglion where no fibers are exchanged, travels through the sphenopalatine foramen (space between the palatine bone, orbital apophysis, and sphenoidal process of the palatine bone) to the posterior part of the nasal cavity



**Figure 2.7** Areas of palate innervated by nasopalatine and greater palatine nerves, and crossover zone.




**Figure 2.8** Course of nasopalatine nerve and entry in palate across maxillary incisive canal.

(Cook 1949). It then passes forward and downward (Figure 2.8) between the mucosa and periosteum of the nasal septum (formed by the inferior side of the sphenoid, the vomer, and the nasal wall), distributing two branches:

- The external branches that innervate the nasal mucosa.
- The *internal branch*, known as the nasopalatine nerve, which reaches the floor of the nasal fossa and enters the nasopalatine canal (or maxillary incisive canal) via the foramina of Stensen before emerging in the oral cavity via the nasopalatine (or incisive) foramen (located at

the midline of the palate, about 3 mm behind the central incisors) immediately below the incisive or interincisive papilla (Figure 2.9) (Annex 41). This branch innervates:

- The fibromucosa, periosteum, and bone around the incisive papilla, the central incisors (100%), the lateral incisors (nearly 50%), and canines (25%) (Table 2.1 and Figure 2.7).
- In some individuals it gives off a branch that contributes to incisor pulp innervation (Hofer 1922; Phillips and Maxmen 1941; Phillips 1943; Cook 1949, 1950b), although that assertion has been challenged by other authors (Olsen et al. 1955; FitzGerald and Scott 1958; Westwater 1960).
- It may often fuse with the anterior superior alveolar nerve plexus (Roda and Blanton 1994).




**Figure 2.9** Course of nasopalatine nerve through maxillary incisive canal and distribution in palate. *Source:* Redrawn from Roberts and Sowray (1987).

**Table 2.1** Nasopalatine nerve innervation of the palatal marginal gingiva (%).

Tooth	Langford 1989 (n = 20)	Calatayud 2001 (n = 24)	Rounded mean
CI	100	96	100%
LI	50	38	50%
C	25	28	25%
First PM	5	4	5%
Second PM	0	0	0%

CI, central incisor; LI, lateral incisor; C, canine; First PM, first premolar; Second PM, second premolar.



**Figure 11.18** DentalVibe.


withdrawn (Shaefer et al. 2017) (Figure 11.19). The disadvantages of the device are as follows:

- 1) It should not be applied to alveolar bone, since this produces an unpleasant sensation.
- 2) Given that the soft tissues are not separated with the fingers, the anatomical structures are not palpated as easily. But this is a clear advantage for some authors, as it removes the need for the dentist to introduce his/her fingers into the patient's mouth during administration of the anesthetic, thus preventing needle stick accidents (David et al. 2007; Fa et al. 2016).

The effectiveness of the technique is addressed in Annex 40. In almost all clinical trials, injection of dental local anesthetic using DentalVibe was less painful than using standard techniques.

### Cartridge Heaters

These are used very little today. Storage of cartridges with sympathomimetic vasoconstrictors such as epinephrine in



**Figure 11.19** Tip of DentalVibe. The cheek is separated from the gums to enable injection in maxillary buccal infiltration. Note the light between the two prongs of the tip.

these heaters for long periods degrades the vasoconstrictor through the action of high temperatures (Fry and Ciarlone 1980).

Experiments that studied the temperature of the cartridge from the point where it leaves the heater until it is placed in the cold metal cartridge-type syringe and the anesthetic solution flows out of the tip of the needle show that the temperature falls considerably until it reaches room temperature (Malamed 2004). This problem could be resolved using modern heaters, which simultaneously heat cartridges, syringes, and needles (Volk and Gargiulo 1984). However, clinical trials show that patients are not able to distinguish an injection at 20–21 °C (room temperature) from one at 35–37 °C (Oikarinen et al. 1975b; Rood 1977; Ram et al. 2002), but they are able to feel less pain when the temperature is higher, 42 °C (107.6 °F) (Aravena et al. 2015, 2018).

## References

- Aldous, J.A. (1968). Needle deflection: a factor in the administration of local anesthetics. *J. Am. Dent. Assoc.* 77 (3): 602–604.
- Alling, C.C. and Christopher, A. (1974). Status report on dental anesthetic needles and syringes. *J. Am. Dent. Assoc.* 89 (5): 1171–1176.
- Annex 10. Maximum doses of local anesthetics in dentistry.
- Annex 14. Injectable anesthetic solutions pH.
- Annex 37. Needle breakage.
- Annex 39. Alkalinized (buffered) local anesthetic solutions.
- Annex 40. Vibration devices.
- Aravena, P.C., Barrientos, C., and Troncoso, C. (2015). Effect of warming anaesthetic solutions on pain during dental injection. A randomized clinical trial. *J. Oral Res.* 4 (5): 306–312.